P-2071. 2023-2024 COVID-19 Vaccine Uptake, Knowledge, and Attitudes among Individuals enrolled in a Household Transmission Study, Tennessee, New York, and Washington, January-April 2024
Authors: Bradford Bertumen J , Benist Sara , South Erin , Ivy Oyegun E , Smith-Jeffcoat Sarah E , Grijalva Carlos G , Zhu Yuwei , Scott Theresa A , Schmitz Jonathan , Chu Helen Y , Weil Ana A , Englund Janet A , MacMillan Melissa P , Stockwell Melissa , McLaren Son H , Sano Ellen , Vargas Celibell , Talbot Keipp , Kirking Hannah L 
Published: January 2025

Abstract

Background
The updated 2023-2024 Coronavirus Disease 2019 (COVID-19) vaccine became available on September 11, 2023 for persons ≥ 6 months old. Understanding the targeted populations’ knowledge, attitudes, and practices regarding this latest vaccine may identify areas to improve future vaccine uptake.Table 1:Participants Characteristics Stratified by Age and Receipt of the 2023-2024 COVID-19 Vaccine

Methods
Persons enrolled in a household transmission investigation of respiratory viruses in Tennessee, New York, and Washington from January–April 2024 were asked to complete an enrollment survey, which included patient demographics and clinical history, and knowledge, attitude, and practice (KAP) questions about recent COVID-19 vaccine recommendations. Surveys for children &lt; 13 years old were completed by their parent or guardian. All persons who answered at least one KAP question and who had verified COVID-19 vaccination information were included in this analysis (Figure 1). Characteristics and responses of recipients and non-recipients of the updated COVID-19 vaccine were described.Table 2:Knowledge, Attitudes and Practices Stratified by Age and Receipt of the 2023-2024 COVID-19 Vaccine

Results
Of 204 individuals included in the analysis, 130 (64%) were adults (≥18 years) and 74 (36%) were children/adolescents (&lt; 18 years) (Figure 1). Ninety-three (72%) adults and 72 (97%) children/adolescents (including everyone aged ≤4 years and 12-17 years) did not receive the 2023-2024 COVID-19 vaccine. Of 93 adults who were non-recipients, those aged 18-49 years (n=63, 68%) represented the most common age group, and 39 (42%) believed they had received the updated vaccine (Table 1 and Table 2). Of the 40 adult non-recipients who responded to the question of why they did not get vaccinated, 13 (33%) stated COVID-19 was not a problem in their community and 8 (20%) adults did not believe the vaccine would prevent COVID-19 or its complications. Of the 40 children/adolescent non-recipients who responded to the same question, 14 (35%) had safety concerns listed as the reason for not receiving the vaccine (Table 2).Table 2:Knowledge, Attitudes and Practices Stratified by Age and Receipt of the 2023-2024 COVID-19 Vaccine (continued)

Conclusion
Uptake of the 2023-2024 COVID-19 vaccine was particularly low in persons aged &lt; 18 years and 18-49 years. Education on the updated vaccination recommendations, the safety of the vaccine, and its effectiveness in preventing complications may improve uptake among these groups. More vaccine uptake and KAP data will be collected with further enrollment.Figure 1:Participant 2023-2024 COVID-19 Vaccine Eligibility and Receipt

Disclosures
Carlos G. Grijalva, MD, MPH, AHRQ: Grant/Research Support|CDC: Grant/Research Support|FDA: Grant/Research Support|Merck: Advisor/Consultant|NIH: Grant/Research Support|SyneosHealth: Grant/Research Support Jonathan Schmitz, MD, PhD, D(ABMM), Biofire/Biomerieux: Grant/Research Support|Genmark/Roche: Grant/Research Support|Pfizer: Honoraria|Vela: Grant/Research Support Helen Y. Chu, MD, MPH, Abbvie: Advisor/Consultant|Merck: Advisor/Consultant|Vir: Advisor/Consultant Janet A. Englund, MD, Abbvie: Advisor/Consultant|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|GlaxoSmithKline: Advisor/Consultant|GlaxoSmithKline: Grant/Research Support|Meissa Vaccines: Advisor/Consultant|Merck: Advisor/Consultant|Pfizer: Board Member|Pfizer: Grant/Research Support|Pfizer: Speaker at meeting|SanofiPasteur: Advisor/Consultant|Shinogi: Advisor/Consultant